Article
Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.
PloS one - 1 Jan 2016
Martin Spencer D, Brown Scott D, Wick Darin A, Nielsen Julie S, Kroeger David R, Twumasi-Boateng Kwame, Holt Robert A, Nelson Brad H
Abstract excerpt
Due to advances in sequencing technology, somatically mutated cancer antigens, or neoantigens, are now readily identifiable and have become compelling targets for immunotherapy. In particular, neoantigen-targeted vaccines have shown promise in several pre-clinical and clinical studies. However, to date, neoantigen-targeted vaccine studies have involved tumors with exceptionally high mutation burdens. It remains...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.